Headache Science & Neurorehabilitation Unit
Pavia, 27100, Italy
Location status: Recruiting
NCT Number: NCT06562413
The investigators aim to define the neurofunctional phenotype of migraine patients who did not respond to at least 3 preventive treatments, including monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) pathway (NON-responders).
Primary aim will be to assess and compare changes in functional resting-state connectivity at baseline and after three months of mAbs treatment between patients who will achieve a reduction of monthly migraine days >/= than 50% (namely Responders) and those who will not (namely Responders).
The 2 groups will undergo a neurofunctional profile by means of High Density-electroencephalogram (HD-EEG) and functional-magnetic resonance imaging (fMRI).
Interested in participating?
Request Info18 year–75 year
All sexes
Observational
Pavia, 27100, Italy
Location status: Recruiting
High Density-electroencephalogram (HD-EEG) and functional-magnetic resonance imaging (fMRI) are widely available as powerful means to non-invasively study brain connectivity features in migraine patients.
They both enables to record brain activity with high spatial resolution. HD-EEG also contributes to high temporal resolution, while fMRI contributes to precise evaluation of deep cortical and subcortical areas, relevant in migraine pathophysiology.
Aim of the study is to evaluate changes in resting-state functional connectivity in patients undergoing preventive mAbs treatment using HD- EEG and fMRI. These findings will allow the identification of a multibiomarkers panel signature of migraine patients resisting to specifically targeted preventive treatments and potentially unveiling other molecular targets for therapeutic approaches.
STUDY DESIGN:
This study is part of the SPHERA project receiving funding from the Italian Ministry of Health (GR-2021-12372429). Patients will be enrolled from those attending the outpatient clinic of IRCCS Mondino Institute (Pavia) and Neurology Department of the University of L'Aquila (Avezzano).
The investigators will collect clinical data and perform neurofunctional profiling of migraine patients at baseline (T0) and after three months of mAbs treatment (T3).
METHODS:
All patients will undergo a resting-state functional evaluation through high density-EEG and subset of 40 patients will also be studied in parallel with fMRI at baseline.
Acquisition parameters will be: High-Pass: 0.5 Hz; Low-Pass: 100 Hz; Notch: 50 Hz. For analysis of HD-EEG data, the investigators will use a tailored analysis pipe-line that was previously developed and validated to reconstruct neural sources from cortical/subcortical gray matter (Semprini, 2021). EEG signals will be band-pass filtered (1-80 Hz) and down-sampled at 250 Hz. Biological artifacts will be rejected using Independent Component Analysis (ICA). EEG signals will be referenced with a customized version of the Reference Electrode Standardization Technique (REST) (Mantini, 2007). A matrix will estimate the relationship between the measured scalp potentials and the dipoles corresponding to brain sources. Sources reconstruction will be performed with the exact low-resolution brain electromagnetic tomography (eLORETA) algorithm.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Monthly or quarterly mAbs administration
Other names: Monoclonal antibody targeting the CGRP pathway (ligand or receptor) (mAbs)
Time frame: Baseline (T0), and three months of mAbs treatment (T1)
Resting state functional connectivity assessed through HD-EEG (continuous variable, without unit of measurement)
Time frame: Baseline (T0)
Resting state functional connectivity assessed through MRI (continuous variable, without unit of measurement)
Time frame: Baseline (T0)
Comparison between RSN-FC changes assessed through HD-EEG (continuous variable, without unit of measurement)
Time frame: Baseline (T0)
Comparison between RSN-FC changes assessed through MRI (continuous variable, without unit of measurement)
Contact information is provided by the study sponsor or research team.
Cinzia Fattore
CONTACT
Roberto De Icco
CONTACT
IRCCS National Neurological Institute "C. Mondino" Foundation
Other
Unraveling the Spectrum of Migraine Resistant to Treatments: Searching for Novel Biological PHEnotypes and theRApeutic Approaches (SPHERA Project)
Acronym: SPHERA_WP1_2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06549270
Brain Diseases, Central Nervous System Diseases
Pavia, Italy
View Trial DetailsNCT06562400
Brain Diseases, Central Nervous System Diseases
Pavia, Italy
View Trial DetailsNCT04715685
Brain Diseases, Central Nervous System Diseases
Aurora, Colorado, United States
View Trial DetailsNCT05415020
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial Details